Hugh M. Davis - Feb 3, 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and COO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Feb 3, 2025
Transactions value $
$0
Form type
4
Date filed
2/4/2025, 04:15 PM
Previous filing
Dec 3, 2024
Next filing
Dec 4, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Award $0 +74.7K $0.00 74.7K Feb 3, 2025 Common Stock 74.7K Direct F1, F2
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +262K $0.00 262K Feb 3, 2025 Common Stock 262K $2.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.